{"id":"octanoic-acid","rwe":[],"tags":[{"label":"octanoic acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G-protein coupled receptor 84","category":"target"},{"label":"GPR84","category":"gene"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"caprylic acid","offLabel":[],"synonyms":["octanoic acid","caprylic acid"],"timeline":[],"approvals":[],"brandName":"Caprylic Acid","ecosystem":[],"mechanism":{"target":"G-protein coupled receptor 84","targets":[{"gene":"GPR84","source":"DrugCentral","target":"G-protein coupled receptor 84","protein":"G-protein coupled receptor 84"}],"modality":"Small Molecule","drugClass":"octanoic acid","explanation":"Imagine your cells have locks on them, and the key to unlocking these locks is a specific molecule that fits perfectly. Caprylic Acid is like a key that fits into one of these locks, allowing it to influence the behavior of the cell. This can lead to changes in how the cell functions, which may be beneficial in treating certain diseases.","oneSentence":"Caprylic Acid works by binding to the G-protein coupled receptor 84, which is involved in various cellular processes.","technicalDetail":"Caprylic Acid exerts its effects by interacting with the G-protein coupled receptor 84, a transmembrane receptor that activates downstream signaling pathways upon ligand binding, leading to changes in cellular behavior and potentially therapeutic effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3998","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OCTANOIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OCTANOIC ACID","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:03:51.346408","biosimilars":[],"competitors":[{"drugName":"dodecanoic acid","drugSlug":"dodecanoic-acid","fdaApproval":"","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"octanoic acid","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dodecanoic-acid","brandName":"dodecanoic acid","genericName":"dodecanoic acid","approvalYear":"","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07089498","phase":"NA","title":"13C-Octanoic Acid Breath Test on Gastric Emptying in Celiac Patients With Functional Disorders","status":"COMPLETED","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2021-02-03","conditions":["Functional Gastrointestinal Disorders"],"enrollment":68,"completionDate":"2024-04-30"},{"nctId":"NCT06358573","phase":"PHASE2","title":"Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-24","conditions":["Triple-negative Breast Cancer","TNBC - Triple-Negative Breast Cancer"],"enrollment":54,"completionDate":"2029-12"},{"nctId":"NCT06170346","phase":"PHASE2","title":"Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced","status":"COMPLETED","sponsor":"Universitas Padjadjaran","startDate":"2022-11-01","conditions":["Photodamaged Skin"],"enrollment":11,"completionDate":"2024-01-31"},{"nctId":"NCT05794243","phase":"PHASE1","title":"A Multiple-Dose Study of LY3493269 in Healthy Participants","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2023-03-23","conditions":["Healthy"],"enrollment":42,"completionDate":"2023-06-20"},{"nctId":"NCT04682106","phase":"PHASE1","title":"A Study of LY3493269 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-05-03","conditions":["Healthy"],"enrollment":40,"completionDate":"2021-11-11"},{"nctId":"NCT02014649","phase":"PHASE1,PHASE2","title":"Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza","status":"TERMINATED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2013-11","conditions":["Influenza"],"enrollment":15,"completionDate":"2014-05"},{"nctId":"NCT01902381","phase":"PHASE2","title":"CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-08","conditions":["Previously Treated Myelodysplastic Syndromes"],"enrollment":12,"completionDate":"2018-11-26"},{"nctId":"NCT02484391","phase":"PHASE1","title":"CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-09","conditions":["Granulocytic Sarcoma","Recurrent Adult Acute Myeloid Leukemia"],"enrollment":48,"completionDate":"2022-02-02"},{"nctId":"NCT06595680","phase":"PHASE2","title":"Development of an Innovative Hemodialysis Method to Improve Dialytic Clearance of Protein-bound Uremic Toxins","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-01-01","conditions":["End Stage Renal Disease","Chronic Hemolysis"],"enrollment":12,"completionDate":"2027-01-22"},{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":["Diabetes Complications","Diabetes Mellitus","Diabetic Neuropathies"],"enrollment":13,"completionDate":"2022-02-01"},{"nctId":"NCT02168140","phase":"PHASE1","title":"CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-09","conditions":["Adult Lymphocyte Depletion Hodgkin Lymphoma","Adult Lymphocyte Predominant Hodgkin Lymphoma","Adult Mixed Cellularity Hodgkin Lymphoma","Adult Nasal Type Extranodal NK/T-cell Lymphoma","Adult Nodular Sclerosis Hodgkin Lymphoma","Anaplastic Large Cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Hepatosplenic T-cell Lymphoma","Noncutaneous Extranodal Lymphoma","Peripheral T-cell Lymphoma","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Hodgkin Lymphoma","Recurrent Adult T-cell Leukemia/Lymphoma","Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma","Recurrent Mycosis Fungoides/Sezary Syndrome","T-cell Adult Acute Lymphoblastic Leukemia","T-cell Large Granular Lymphocyte Leukemia"],"enrollment":16,"completionDate":"2022-09-15"},{"nctId":"NCT06005415","phase":"NA","title":"Glycemic Response to an Innovative Cookie to Promote Human Health","status":"COMPLETED","sponsor":"KU Leuven","startDate":"2023-09-05","conditions":["Postprandial Glycemic Responses"],"enrollment":55,"completionDate":"2023-11-24"},{"nctId":"NCT04566692","phase":"PHASE4","title":"A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-11-24","conditions":["Primary Immunodeficiency"],"enrollment":33,"completionDate":"2022-07-25"},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":["Small Fiber Neuropathy","Idiopathic Peripheral Neuropathy"],"enrollment":20,"completionDate":"2022-02-01"},{"nctId":"NCT02232152","phase":"PHASE1","title":"CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-01-06","conditions":["Mucinous Adenocarcinoma of the Colon","Mucinous Adenocarcinoma of the Rectum","Recurrent Colon Cancer","Recurrent Rectal Cancer","Signet Ring Adenocarcinoma of the Colon","Signet Ring Adenocarcinoma of the Rectum","Stage IIIA Colon Cancer","Stage IIIA Rectal Cancer","Stage IIIB Colon Cancer","Stage IIIB Rectal Cancer","Stage IIIC Colon Cancer","Stage IIIC Rectal Cancer","Stage IVA Colon Cancer","Stage IVA Rectal Cancer","Stage IVB Colon Cancer","Stage IVB Rectal Cancer"],"enrollment":19,"completionDate":"2023-01-11"},{"nctId":"NCT01835041","phase":"PHASE1","title":"CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-04","conditions":["Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage IV Pancreatic Cancer"],"enrollment":21,"completionDate":"2023-03-16"},{"nctId":"NCT02794805","phase":"PHASE2","title":"Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2015-06","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":74,"completionDate":"2017-04"},{"nctId":"NCT02314026","phase":"PHASE2","title":"BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH","status":"COMPLETED","sponsor":"Meridian Bioscience, Inc.","startDate":"2015-03","conditions":["Non-Alcoholic Steatohepatitis"],"enrollment":140,"completionDate":"2017-06"},{"nctId":"NCT01433016","phase":"PHASE2","title":"Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI","status":"TERMINATED","sponsor":"Meridian Bioscience, Inc.","startDate":"2011-11","conditions":["Chronic Liver Disease","Hepatocellular Carcinoma (HCC)"],"enrollment":20,"completionDate":"2013-05"},{"nctId":"NCT05586295","phase":"NA","title":"Vitamin B Complex Improved Exercise Performance and Anti-fatigue","status":"COMPLETED","sponsor":"National Taiwan Sport University","startDate":"2021-03-03","conditions":["Exercise Performance","Fatigue"],"enrollment":32,"completionDate":"2021-06-26"},{"nctId":"NCT04480424","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-17","conditions":["COVID-19"],"enrollment":100,"completionDate":"2021-10-25"},{"nctId":"NCT04886882","phase":"EARLY_PHASE1","title":"Topical Agents Containing Magnesium Sulfate & Wound Healing in the Rat Model","status":"UNKNOWN","sponsor":"Başakşehir Çam & Sakura City Hospital","startDate":"2021-03-22","conditions":["Wound Heal"],"enrollment":30,"completionDate":"2021-07-01"},{"nctId":"NCT04872946","phase":"NA","title":"Topical and Oral Regimen for Skin Health","status":"COMPLETED","sponsor":"Integrative Skin Science and Research","startDate":"2019-11-26","conditions":["Skin Abnormalities"],"enrollment":74,"completionDate":"2020-05-07"},{"nctId":"NCT02899702","phase":"PHASE4","title":"Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2020-09","conditions":["Staphylococcal Infection","Streptococcal Infection"],"enrollment":0,"completionDate":"2024-09"},{"nctId":"NCT03929211","phase":"PHASE1,PHASE2","title":"CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2021-05","conditions":["Myelodysplastic Syndromes","Progressive Disease"],"enrollment":0,"completionDate":"2027-07"},{"nctId":"NCT04245488","phase":"NA","title":"Sour Taste Intensity Matching With Fatty Acids Taste","status":"COMPLETED","sponsor":"Purdue University","startDate":"2019-05-20","conditions":["Fat Taste"],"enrollment":15,"completionDate":"2019-08-20"},{"nctId":"NCT04095728","phase":"NA","title":"Investigating the Efficacy of Brain Octane® Oil on Cognition, Coordination, Reaction Time and Measurements of Physical Performance in Recreationally Active Adults","status":"COMPLETED","sponsor":"Bulletproof 360, Inc.","startDate":"2019-09-30","conditions":["Healthy"],"enrollment":30,"completionDate":"2020-05-29"},{"nctId":"NCT04550611","phase":"NA","title":"Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-11","conditions":["Guillain-Barre Syndrome"],"enrollment":50,"completionDate":"2022-12"},{"nctId":"NCT03420976","phase":"EARLY_PHASE1","title":"Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth","status":"WITHDRAWN","sponsor":"Atrium Innovations","startDate":"2017-12-07","conditions":["Small Intestinal Bacterial Overgrowth"],"enrollment":0,"completionDate":"2019-02-01"},{"nctId":"NCT03359577","phase":"NA","title":"Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis","status":"COMPLETED","sponsor":"Arctic Nutrition AS","startDate":"2017-11-21","conditions":["Psoriasis Vulgaris"],"enrollment":64,"completionDate":"2019-04-29"},{"nctId":"NCT02806986","phase":"PHASE3","title":"Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2016-06","conditions":["Primary Immunodeficiency"],"enrollment":61,"completionDate":"2019-05-15"},{"nctId":"NCT03896932","phase":"NA","title":"Minipooled-IVIG in Primary Immunodeficiency Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-01-01","conditions":["Primary Immunodeficiency"],"enrollment":15,"completionDate":"2020-05-01"},{"nctId":"NCT02413580","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-03","conditions":["Myasthenia Gravis Exacerbations"],"enrollment":49,"completionDate":"2018-04"},{"nctId":"NCT02883751","phase":"NA","title":"Phototherapy in DM Amputation Ulcers.","status":"WITHDRAWN","sponsor":"University of Nove de Julho","startDate":"2017-01","conditions":["Diabetes Mellitus","Amputation Stumps","Diabetic Foot"],"enrollment":0,"completionDate":"2020-12"},{"nctId":"NCT02693106","phase":"NA","title":"Evaluation of the Ketogenic Potential of Different Diet Supplements","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2013-07","conditions":["Healthy Adults"],"enrollment":13,"completionDate":"2015-06"},{"nctId":"NCT02249910","phase":"PHASE1","title":"Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-09-18","conditions":["Diabetes","Healthy"],"enrollment":32,"completionDate":"2015-03-06"},{"nctId":"NCT01468948","phase":"PHASE1","title":"Octanoic Acid for Essential Tremor","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2011-10-28","conditions":["Essential Tremor"],"enrollment":18,"completionDate":"2012-07-18"},{"nctId":"NCT03063229","phase":"NA","title":"Energy Balance Following Islet Transplantation","status":"TERMINATED","sponsor":"University of Edinburgh","startDate":"2016-06","conditions":["Type 1 Diabetes"],"enrollment":2,"completionDate":"2019-10-23"},{"nctId":"NCT02604810","phase":"PHASE3","title":"Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2016-01","conditions":["Primary Immunodeficiency"],"enrollment":53,"completionDate":"2017-12"},{"nctId":"NCT03512145","phase":"NA","title":"Clinical Evaluation of the VIPUN Balloon Catheter 0.2 in Critically Ill Patients","status":"COMPLETED","sponsor":"Prof Dr Jan Tack","startDate":"2018-04-16","conditions":["Critical Illness","Intolerance; Nutritional","Delayed Gastric Emptying","Gastric Motor Dysfunction"],"enrollment":30,"completionDate":"2019-08-30"},{"nctId":"NCT01766219","phase":"PHASE1,PHASE2","title":"CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-05","conditions":["Adult Primary Cholangiocellular Carcinoma","Advanced Adult Primary Liver Cancer","Cholangiocarcinoma of the Extrahepatic Bile Duct","Cholangiocarcinoma of the Gallbladder","Localized Unresectable Adult Primary Liver Cancer","Metastatic Extrahepatic Bile Duct Cancer","Recurrent Adult Primary Liver Cancer","Recurrent Extrahepatic Bile Duct Cancer","Unresectable Extrahepatic Bile Duct Cancer"],"enrollment":17,"completionDate":"2018-05-18"},{"nctId":"NCT03904433","phase":"NA","title":"Quantification of Ketosis After Intake of Coconut Oil and Caprylic Acid-With and Without Glucose-After a 12-hour Fast","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2018-08-24","conditions":["Aged"],"enrollment":15,"completionDate":"2018-10-12"},{"nctId":"NCT03664570","phase":"NA","title":"Enteral Nutrition Infusion Rate and Gastric Function","status":"COMPLETED","sponsor":"Prof Dr Jan Tack","startDate":"2018-10-03","conditions":["Healthy"],"enrollment":19,"completionDate":"2019-04-05"},{"nctId":"NCT03460444","phase":"NA","title":"The Effect of Raising Ketones Directly With MCT Oil on Inflammation in Healthy Young Adults","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2018-03-20","conditions":["MCT Oil Supplementation"],"enrollment":15,"completionDate":"2019-02-04"},{"nctId":"NCT00115778","phase":"PHASE2","title":"Intravenous Immunoglobulin (IVIG) in Lung Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2005-06","conditions":["Hypogammaglobulinemia","Lung Transplantation"],"enrollment":11,"completionDate":"2010-08"},{"nctId":"NCT02473952","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-08","conditions":["Myasthenia Gravis, Generalized"],"enrollment":62,"completionDate":"2018-01"},{"nctId":"NCT01839981","phase":"PHASE1","title":"CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-07","conditions":["Acinar Cell Adenocarcinoma of the Pancreas","Duct Cell Adenocarcinoma of the Pancreas","Recurrent Pancreatic Cancer","Stage III Pancreatic Cancer","Stage IV Pancreatic Cancer"],"enrollment":10,"completionDate":"2015-10"},{"nctId":"NCT01864525","phase":"PHASE1,PHASE2","title":"Effects of Octanoic Acid for Treatment of Essential Voice Tremor","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2013-07","conditions":["Essential Voice Tremor","Vocal Tremor","Voice Tremor","Essential Tremor of Voice"],"enrollment":17,"completionDate":"2017-03-31"},{"nctId":"NCT03370159","phase":"PHASE1,PHASE2","title":"CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06","conditions":["Stage IIIB Non-Small Cell Lung Cancer AJCC v7","Stage IV Non-Small Cell Lung Cancer AJCC v7"],"enrollment":0,"completionDate":"2020-03-01"},{"nctId":"NCT03410147","phase":"NA","title":"A Dose-finding and Feasibility Study for a Prolonged 13C-octanoate Breath Test for Gastric Emptying","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2018-02-09","conditions":["Healthy","Gastric Emptying"],"enrollment":4,"completionDate":"2018-03-29"},{"nctId":"NCT02397577","phase":"NA","title":"Reference Values for Gastric Emptying","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-02","conditions":["Delayed Gastric Emptying"],"enrollment":75,"completionDate":"2018-05-01"},{"nctId":"NCT02472626","phase":"PHASE1,PHASE2","title":"6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2015-12","conditions":["Untreated Adult Acute Myeloid Leukemia"],"enrollment":0,"completionDate":"2016-07"},{"nctId":"NCT01931787","phase":"PHASE1","title":"CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2013-10","conditions":["Recurrent Small Cell Lung Cancer"],"enrollment":15,"completionDate":"2015-12"},{"nctId":"NCT02168907","phase":"PHASE1","title":"CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-12","conditions":["B-cell Adult Acute Lymphoblastic Leukemia","B-cell Chronic Lymphocytic Leukemia","Cutaneous B-cell Non-Hodgkin Lymphoma","Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Intraocular Lymphoma","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Acute Lymphoblastic Leukemia","Recurrent Adult Burkitt Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Adult Diffuse Mixed Cell Lymphoma","Recurrent Adult Diffuse Small Cleaved Cell Lymphoma","Recurrent Adult Grade III Lymphomatoid Granulomatosis","Recurrent Adult Immunoblastic Large Cell Lymphoma","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Mycosis Fungoides/Sezary Syndrome","Recurrent Small Lymphocytic Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Hairy Cell Leukemia","Small Intestine Lymphoma","Splenic Marginal Zone Lymphoma","Testicular Lymphoma","Waldenström Macroglobulinemia"],"enrollment":1,"completionDate":"2015-02"},{"nctId":"NCT01793883","phase":"PHASE2","title":"Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2013-05","conditions":["Influenza"],"enrollment":639,"completionDate":"2014-05"},{"nctId":"NCT02022761","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma","status":"COMPLETED","sponsor":"Biota Scientific Management Pty Ltd","startDate":"2013-10","conditions":["Asthma"],"enrollment":32,"completionDate":"2014-02"},{"nctId":"NCT03467737","phase":"NA","title":"Assessment of Starch Digestibility and Amylase Sufficiency in Children","status":"COMPLETED","sponsor":"Purdue University","startDate":"2012-12-01","conditions":["Malnutrition, Child"],"enrollment":54,"completionDate":"2016-07-01"},{"nctId":"NCT00861809","phase":"PHASE2","title":"The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":["Gastroparesis"],"enrollment":11,"completionDate":"2010-11"},{"nctId":"NCT01039805","phase":"PHASE2","title":"Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-12","conditions":["Gastroparesis"],"enrollment":34,"completionDate":"2011-07"},{"nctId":"NCT01520805","phase":"PHASE2","title":"Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome","status":"WITHDRAWN","sponsor":"Cornerstone Pharmaceuticals","startDate":"2016-01","conditions":["Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)"],"enrollment":0,"completionDate":"2018-12"},{"nctId":"NCT01832857","phase":"PHASE2","title":"Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients","status":"TERMINATED","sponsor":"Cornerstone Pharmaceuticals","startDate":"2013-06","conditions":["Cancer"],"enrollment":7,"completionDate":"2016-12"},{"nctId":"NCT02372149","phase":"PHASE4","title":"IVIg for Demyelination in Diabetes Mellitus","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2015-02","conditions":["Peripheral Neuropathy","Diabetes Mellitus","Chronic Inflammatory Demyelinating Polyneuropathy"],"enrollment":25,"completionDate":"2018-02"},{"nctId":"NCT02639130","phase":"PHASE4","title":"GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes","status":"COMPLETED","sponsor":"Diabeteszentrum Bad Lauterberg im Harz","startDate":"2008-02","conditions":["Type 2 Diabetes"],"enrollment":67,"completionDate":"2010-01"},{"nctId":"NCT02602158","phase":"EARLY_PHASE1","title":"13C Trioctanoate Breath Test as a Measurement of Gastric Fat Volume Emptying","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-10","conditions":["Healthy"],"enrollment":32,"completionDate":"2016-04"},{"nctId":"NCT00220727","phase":"PHASE2","title":"Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2003-07","conditions":["Purpura, Thrombocytopenic, Idiopathic"],"enrollment":8,"completionDate":"2003-10"},{"nctId":"NCT00220779","phase":"PHASE2","title":"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-12","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":128,"completionDate":"2005-02"},{"nctId":"NCT02246543","phase":"NA","title":"Whey Protein Study - Identification of Sustainable Satiety","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2013-08","conditions":["Satiety"],"enrollment":13,"completionDate":"2015-10"},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":["Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"],"enrollment":117,"completionDate":"2006-06"},{"nctId":"NCT00220805","phase":"PHASE2","title":"Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-01","conditions":["Macular Degeneration"],"enrollment":96,"completionDate":"2005-05"},{"nctId":"NCT01244503","phase":"PHASE2","title":"Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)","status":"TERMINATED","sponsor":"Virginia Commonwealth University","startDate":"2011-02","conditions":["Metabolic Syndrome","Nonalcoholic Fatty Liver Disease"],"enrollment":61,"completionDate":"2012-06"},{"nctId":"NCT00389324","phase":"PHASE2","title":"A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2006-11","conditions":["Immunologic Deficiency Syndrome"],"enrollment":35,"completionDate":"2008-08"},{"nctId":"NCT02415283","phase":"","title":"OBT Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2015-05","conditions":["HCC"],"enrollment":2,"completionDate":"2016-12"},{"nctId":"NCT01465958","phase":"PHASE4","title":"Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2011-11","conditions":["Primary Immunodeficiency"],"enrollment":12,"completionDate":"2013-10"},{"nctId":"NCT00592072","phase":"NA","title":"Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-07","conditions":["Diabetes Mellitus, Type 1"],"enrollment":12,"completionDate":"2008-07"},{"nctId":"NCT02139657","phase":"PHASE1","title":"An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2014-03","conditions":["Rabies"],"enrollment":12,"completionDate":"2014-05"},{"nctId":"NCT01830322","phase":"PHASE2","title":"Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Cornerstone Pharmaceuticals","startDate":"2014-01","conditions":["Metastatic Pancreatic Adenocarcinoma"],"enrollment":0,"completionDate":"2018-12"},{"nctId":"NCT00848172","phase":"PHASE1,PHASE2","title":"Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2009-02","conditions":["Essential Tremor"],"enrollment":29,"completionDate":"2010-11"},{"nctId":"NCT01281059","phase":"NA","title":"Prediction of Severity of Liver Disease Non Alcoholic Fatty Liver Disease in Patients With Suspected NAFLD by a 13C Octanoate Breath Test","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2011-01","conditions":["NAFLD"],"enrollment":0,"completionDate":""},{"nctId":"NCT01456572","phase":"PHASE1","title":"Gastric and Intestinal Satiation in Obese and Normal Weight Healthy People","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2007-01","conditions":["Endocrine System Diseases"],"enrollment":65,"completionDate":"2011-07"},{"nctId":"NCT01115049","phase":"PHASE4","title":"Hexetidine and Chlorobutanol for Lesions Due to Prostheses","status":"COMPLETED","sponsor":"Federico II University","startDate":"2010-02","conditions":["Oral Mucositis"],"enrollment":44,"completionDate":"2010-03"},{"nctId":"NCT00220766","phase":"PHASE3","title":"Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-08","conditions":["Immunologic Deficiency Syndrome","Agammaglobulinemia","Severe Combined Immunodeficiency","Wiskott-Aldrich Syndrome","Common Variable Immunodeficiency"],"enrollment":100,"completionDate":"2004-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000183249","NDDF":"002897","UNII":"OBL58JN025","VUID":"4030979","CHEBI":"CHEBI:28837","VANDF":"4030979","INN_ID":"5433","RXNORM":"20178","UMLSCUI":"C0054616","ChEMBL_ID":"CHEMBL324846","KEGG_DRUG":"D05220","DRUGBANK_ID":"DB04519","PDB_CHEM_ID":"OCA","PUBCHEM_CID":"379","IUPHAR_LIGAND_ID":"4585","MESH_SUPPLEMENTAL_RECORD_UI":"C031492"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1959,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Caprylic acid is used in the formulation of Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, which is being studied for the treatment of various immunodeficiency conditions, including Immunologic Deficiency Syndrome, Agammaglobulinemia, and Common Variable Immunodeficiency. The exact mechanism of caprylic acid in this context is not specified in the provided information, but it is used as a component of the immune globulin formulation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}